Abstract Library

#1549 Ectopic Cushing Syndrome in a Patient with Metastatic Medullary Thyroid Carcinoma

Introduction: Ectopic Cushing syndrome was reported in 0.6% of patients with medullary thyroid carcinoma; it usually occurred in metastatic cases and significantly increases mortality.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Poiana C

Authors: Trifanescu R, Caragheorgheopol A, Schipor S, Dumitrascu A, Baciu I,

Keywords: Ectopic Cushing syndrome, medullary thyroid carcinoma,

#1453 Clinicopathologic Features, Treatments and Survival of Patients with Ectopic Cushing’s Syndrome from Neuroendocrine Tumors: Data from an Italian Multicenter Study

Introduction: Literature on ectopic Cushing syndrome (ECS) and NET is scarce

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Davì M

Authors: Davì M, Cosaro E, Piacentini S, Reimondo G, Albiger N,

Keywords: Ectopic ACTH,

#1143 Ectopic Cushing’s Syndrome (ECS) in Patients with Neuroendocrine Neoplasms

Introduction: Ectopic Cushing syndrome (ECS) has been described in patients with neuroendocrine neoplasms (NENs)

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author: Chatzellis E

Authors: Alexandraki K, Boutzios G, Papaoikonomou E, Chatzellis E, Chrysochoou M,

Keywords: ECS,

#858 Metastatic Pancreatic Neuroendocrine Tumors with Ectopic Cushing Syndrome: Could Everolimus Be a Safe Therapeutic Option?

Introduction: Everolimus(E) has proved effective in prolonging PFS in advanced P-NETs. As E is a substrate of CYP3A4 co-administration with ketoconazole (k), a strong inhibitor of CYP3A4 used to control hypercortisolism, should be avoided.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author: davi' m

Authors: Davì M, Cingarlini S, Butturini G, Capelli P, Scarpa A,

Keywords: Everolimus, pancreatic NET, ectopic Cushing syndrome,